Onesource Specialty Pharma Ltd
NSE:ONESOURCE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Onesource Specialty Pharma Ltd
Income from Continuing Operations
Onesource Specialty Pharma Ltd
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
O
|
Onesource Specialty Pharma Ltd
NSE:ONESOURCE
|
Income from Continuing Operations
-₹172.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Divi's Laboratories Ltd
NSE:DIVISLAB
|
Income from Continuing Operations
₹24.8B
|
CAGR 3-Years
1%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Syngene International Ltd
NSE:SYNGENE
|
Income from Continuing Operations
₹3.5B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
5%
|
|
|
A
|
Akums Drugs and Pharmaceuticals Ltd
NSE:AKUMS
|
Income from Continuing Operations
₹3.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Sai Life Sciences Ltd
NSE:SAILIFE
|
Income from Continuing Operations
₹1.7B
|
CAGR 3-Years
201%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
A
|
Anthem Biosciences Ltd
NSE:ANTHEM
|
Income from Continuing Operations
₹4.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Onesource Specialty Pharma Ltd
Glance View
Onesource Specialty Pharma Ltd is a IN-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Bangalore, Karnataka and currently employs 525 full-time employees. The company went IPO on 2025-01-24. OneSource Specialty Pharma Limited is an India-based vertically integrated biopharma service company with the capabilities to develop and manufacture complex biologics, biosimilars and vaccines. The company operates as a specialty pharma pure-play contract development and manufacturing organization (CDMO). The firm specializes in prefilled syringes (with or without a safety device), dial and push variable and fixed dose pen injectors, pull push fixed dose pens and autoinjectors. Its integrated services offer comprehensive biologics solutions. The company supports the development of complex biologics, including microbial and mammalian cell line biopharmaceuticals, cell and gene therapy and ribonucleic acid (RNA) products. The firm caters to a variety of capsule shapes and sizes, as well as formulations, traditional softgels to enteric coated capsules, vegan alternatives, chewable formats, vaginal pessaries, liposomal capsules, applicaps, and suppositories.
See Also
What is Onesource Specialty Pharma Ltd's Income from Continuing Operations?
Income from Continuing Operations
-172.8m
INR
Based on the financial report for Mar 31, 2025, Onesource Specialty Pharma Ltd's Income from Continuing Operations amounts to -172.8m INR.
What is Onesource Specialty Pharma Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 1Y
95%
Over the last year, the Income from Continuing Operations growth was 95%.
